CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for radiation oncologists, medical oncologists, oncology fellows and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).
  
  OVERVIEW OF ACTIVITY
  Non-small cell lung cancer (NSCLC) accounts for 84% of all cases of lung cancer, and within that population approximately one third of patients present with locally advanced Stage III disease. Expected 5-year survival rates for these patients range from 36% (Stage IIIA) to 13% (Stage IIIC). Therefore, the clinical care of these individuals remains one of the major challenges faced in solid tumor oncology. Recent breakthroughs in disease management for these patients have led to the advent of new treatment modalities, including the use of immunotherapy. But while immune checkpoint inhibitors have reshaped the management of locally advanced lung cancer, a number of controversies and questions remain with regard to the current application and future role of these agents in clinical practice.
  
  This CME program, developed from the proceedings of a satellite symposium held during the 2019 ASTRO Annual Meeting, features discussions with leading lung cancer investigators regarding the role of immune checkpoint inhibitors in the management of locally advanced NSCLC. By providing information on important developments, this activity will assist medical oncologists and other healthcare professionals to address uncertainties in the care of patients with this disease.
  
  LEARNING OBJECTIVES
  

  • Understand the biologic basis for the investigation of immune checkpoint inhibitors in combination with chemoradiation therapy for nonmetastatic NSCLC.
  • Appreciate the FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after concurrent chemoradiation therapy, and discern how this strategy can be appropriately and safely integrated into routine clinical practice.
  • Consider the available data and investigator perspectives regarding the efficacy of immune checkpoint inhibitors for patients with locally advanced NSCLC with or without targetable mutations.
  • Recognize immune-related adverse events associated with the use of immune checkpoint inhibitors, and offer supportive strategies to minimize and/or manage these toxicities.
  • Recall emerging data with novel approaches and strategies using immune checkpoint inhibitors for patients with NSCLC, and consider how this information may be applied in future clinical practice.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  MODERATOR
  
  Corey J Langer, MD
  Director of Thoracic Oncology
  Abramson Cancer Center
  Professor of Medicine
  Perelman School of Medicine
  University of Pennsylvania
  Philadelphia, Pennsylvania
  
  Advisory Committee and Consulting Agreements: AbbVie Inc, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Lilly, Merck, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Advantage Pharmaceuticals, GlaxoSmithKline, Inovio Pharmaceuticals Inc, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Lilly, Merck, Takeda Oncology; Data and Safety Monitoring Board: Amgen Inc, Incyte Corporation, Lilly, SWOG.
  
  FACULTY
  
  Shruti Jolly, MD
  Professor, Department of Radiation Oncology
  Chief of Brachytherapy Services
  Associate Chair of Community Practices
  Associate Medical Director, UMHS Strategic Planning and Business Development
  University of Michigan
  Ann Arbor, Michigan
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Varian Medical Systems Inc.
  
  Billy Wiseman Loo Jr, MD, PhD
  Professor, Thoracic Radiation Oncology
  Program Leader
  Department of Radiation Oncology
  Stanford University School of Medicine
  Stanford, California
  
  Advisory Committee: Varian Medical Systems Inc; Other: Founder and board member of TibaRay Inc.
  
  Jyoti D Patel, MD
  Professor of Medicine
  Director, Thoracic Oncology
  The University of Chicago
  Chicago, Illinois
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Takeda Oncology.
  
  RESEARCH TO PRACTICE PRESIDENT NEIL LOVE, MD — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: November 2019
  Expiration date: November 2020